NAAG Urges OfferUp to Prevent the Sales of Fraudulent Vaccine Cards

The false and deceptive marketing and sales of fake COVID vaccine cards threatens the health of our communities, slows progress in getting our residents protected from the virus, and are a violation of the laws of many states.

Read More →

NAAG Works to Prevent the Online Sale of Fraudulent COVID Vaccination Cards

The false and deceptive marketing and sales of fake COVID vaccine cards threaten the health of our communities, slow progress in getting our residents protected from the virus, and are a violation of the laws of many states.

Read More →

NAAG Sends Letter to USDOJ Condemning January 6 Violence at U.S. Capitol

We all just witnessed a very dark day in America. The events of January 6 represent a direct, physical challenge to the rule of law and our democratic republic itself. Together, we will continue to do our part to repair the damage done to institutions and build a more perfect union. As Americans, and those charged with enforcing the law, we must come together to condemn lawless violence, making clear that such actions will not be allowed to go unchecked.

Read More →

NAAG Supports Daniel’s Law

The Daniel Anderl Judicial Security and Privacy Act honors the memory of the son of Judge Esther Salas of the U.S. District Court for the District of New Jersey. Daniel was tragically killed on July 19, 2020, when an armed assailant—a deranged attorney who had appeared in a case before Judge Salas—appeared at her home and opened fire. Daniel was only 20. Judge Salas’s husband was also shot in the attack. 

Read More →

NAAG Urges Congress to Pass Safeguarding America’s First Responders Act

This legislation ensures that families of officers and first responders lost while fighting the pandemic do not face unnecessary barriers to benefits they have already been promised.

Read More →

NAAG Works to Expose Illegal Robocallers

State Attorneys General have long been leaders in the fight against illegal robocallers and their assault on the American people’s privacy.

Read More →

Attorneys General Urge Congress to Adopt Key Changes to the Victims of Crime Act (VOCA)

As state Attorneys General, we are often the administrators of grant funding, through our state compensation programs or otherwise, financed directly from the Fund. In order to ensure the predictability and sustainability of these critical funds, change must be enacted to support our states’ ability to effectively serve victims and survivors of crime for years to come.

Read More →

NAAG Endorses Stopping Overdoses of Fentanyl Analogues (SOFA) Act

States and localities are on the front line of this crisis and are a large part of winning the battle from both a law enforcement and public health perspective.

Read More →

New York et al. v. Cephalon, No. 2:16-cv-04234 (E.D. Pa. Aug. 4, 2016)

In May 2015, the FTC settled a “pay-for-delay” suit against Cephalon for injunctive relief and $1.2 billion, which was paid into an escrow account. The FTC settlement allowed for those escrow funds to be distributed for settlement of certain related cases and government investigations. In August 2016, forty-eight states filed suit in the Eastern District of Pennsylvania against Cephalon alleging anticompetitive conduct by Cephalon to protect the profits it earned from having a patent-protected monopoly on the sale of its landmark drug, Provigil. According to the complaint, Cephalon’s conduct delayed generic versions of Provigil from entering the market for several years. The complaint alleged that as patent and regulatory barriers that prevented generic competition to Provigil neared expiration, Cephalon intentionally defrauded the Patent and Trademark Office to secure an additional patent, which a court subsequently deemed invalid and unenforceable. Before it was declared invalid, Cephalon was able to use the patent to delay generic competition for nearly six additional years by filing patent infringement lawsuits. Cephalon settled those lawsuits by paying competitors to delay sale of their generic versions of Provigil until at least April 2012. Consumers, states, and others paid millions more for Provigil than they would have had generic versions of the drug launched by early 2006, as expected. A settlement was filed with the complaint, which includes $35 million for distribution to consumers who bought Provigil.

Read More →

Maryland et al. v. Perrigo Company, No. 1:04CV01398 (D.D.C. Aug. 17, 2004)

The FTC and states alleged that the companies had entered into a “pay-for-delay” arrangement, whereby Perrigo paid Alpharma to withdraw its generic version from the market for Children’t ibuprofen.According to the complaint, in June 1998, Perrigo and Alpharma signed an agreement allocating to Perrigo the sale of OTC children’s liquid ibuprofen for seven years. In exchange for agreeing not to compete, Alpharma received an up-front payment and a royalty on Perrigo’s sales of children’s liquid ibuprofen. The FTC received $6.25 million to compensate injured consumers. The states received $1.5 million in lieu of civil penalties. the parties were enjoined from future agreements.

Read More →